Study of Microbiome and Metabolite Changes in IgA Nephropathy Patients Observing Effects Without Recent Antibiotic or Immunosuppressant Treatment

What this Trial Is About

IgA Nephropathy IgAN is the most common primary glomerulonephritis in China, marked by deposits of a specific antibody called galactose-deficient IgA1 in the kidney. This antibody is thought to originate from mucosa-associated lymphoid tissue and is triggered by bacteria exposure. Researchers are exploring how the microbes in the mouth and throat relate to IgAN since this link is currently unclear. The study aims to develop a model using mucosa-specific microbes and clinical data to aid early diagnosis and gain insights into potential treatments for IgAN. This observational study will enroll IgAN patients who have not used glucocorticoids, immunosuppressants for six months, or antibiotics for one month, along with their family members. Samples including feces, urine, blood, oral mucosal swabs, and throat swabs will be collected for analysis of microbial and metabolic profiles. Additional samples will be gathered from IgAN patients at two and six months to monitor changes in bacterial communities and metabolites in relation to disease progression. Participants will undergo multiple sample collections over time to assess microflora and metabolite changes. Researchers will analyze these data alongside clinical indicators to understand disease development better. The primary measures include counting participants with any cause of death or those who do not meet entry criteria within six months after enrollment. The study duration and follow-up continue for at least six months, with safety and disease status monitored throughout.

Correlation of Microbiome and Metabonomics With IgA Nephropathy